Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment

A. Abbara¹ | R. Islam² | S.A. Clarke¹ | L. Jeffers¹ | G. Christopoulos² | A.N. Comninos¹ | R. Salim² | S.A. Lavery² | T.N.L. Vuong³,⁴ | P. Humaidan⁵ | T.W. Kelsey⁶ | G.H. Trew² | W.S. Dhillo¹

¹Hammersmith Hospital, Imperial College London, London, UK
²IVF Unit, Hammersmith Hospital, London, UK
³University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
⁴My Duc Hospital, IVFMD, Ho Chi Minh City, Vietnam
⁵The Fertility Clinic, Skive Regional Hospital and Faculty of Health Aarhus University, Aarhus, Denmark
⁶School of Computer Science, University of St Andrews, St Andrews, UK

Summary
Objective: Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic condition, predominantly related to the hormone used to induce oocyte maturation during IVF treatment. Kisspeptin is a hypothalamic neuropeptide that has recently been demonstrated to safely trigger final oocyte maturation during IVF treatment even in women at high risk of OHSS. However, to date, the safety of kisspeptin has not been compared to current hormonal triggers of oocyte maturation.

Design: We conducted a retrospective single-centre cohort study investigating symptoms and clinical parameters of early OHSS in women at high risk of OHSS (antral follicle count or total number of follicles on day of trigger ≥23) triggered with human chorionic gonadotrophin (hCG) (n = 40), GnRH agonist (GnRHa; n = 99) or kisspeptin (n = 122) at Hammersmith Hospital IVF unit, London, UK (2013-2016).

Results: Clinical Parameters of OHSS: Median ovarian volume was larger following hCG (138 ml) than GnRHa (73 ml; P < .0001), and in turn kisspeptin (44 ml; P < .0001). Mean ascitic volumes were lesser following GnRHa (9 ± 44 ml) and kisspeptin (5 ± 8 ml) than hCG (62 ± 84 ml; P < .0001). Symptoms of OHSS were most frequent following hCG, least frequent following kisspeptin.

Diagnosis of OHSS: The odds ratio for OHSS diagnosis was 33.6 (CI 12.6-89.5) following hCG and 3.6 (CI 1.8-7.1) following GnRHa, when compared to kisspeptin.

Conclusion: Triggering oocyte maturation by inducing endogenous gonadotrophin release is preferable to the use of exogenous hCG in women at high risk of OHSS.

Keywords
GnRH agonist, hCG, IVF, kisspeptin, ovarian hyperstimulation syndrome
1 | INTRODUCTION

Ovarian hyperstimulation syndrome (OHSS) is a largely iatrogenic condition that is associated with significant morbidity and even mortality in otherwise healthy women undergoing fertility treatment. The hormone used to induce oocyte maturation plays a critical role in the risk of OHSS following IVF treatment, with exogenous human chorionic gonadotrophin (hCG) being the most frequent aetiological agent. Ovarian hyperstimulation syndrome results from the release of vasoactive substances from the ovary, such as vascular endothelial growth factor (VEGF A) due to excessive ovarian stimulation after triggering oocyte maturation during IVF treatment. This leads to increased capillary permeability and fluid shifts from the intravascular compartment into the third space of the body. Thus, OHSS is characterised by ovarian enlargement, ascites, pleural effusion, oliguria, haemoconcentration and thromboembolic events.

Ovarian hyperstimulation syndrome can be further categorised as early (≤9 days following trigger administration) or late (≥10 days) OHSS, to reflect differences in pathophysiology. Early OHSS results from excessive stimulation of the ovaries, usually due to the administration of hCG to trigger oocyte maturation. By contrast, late OHSS occurs due to the production of endogenous hCG from a developing pregnancy. Consequently, early OHSS is regarded as predominantly trigger-related, whereas late OHSS is regarded as predominantly pregnancy-related. Cryopreservation of embryos with transfer in later cycles (segmentation) can be used to manage the risk of OHSS, although logically, segmentation can only mitigate the occurrence of late OHSS. The risk of early OHSS can more reliably be mitigated using alternative triggers of oocyte maturation (hCG, GnRHa or kisspeptin) in women at high risk of early OHSS (antral follicle count or total number of follicles on day of trigger ≥23).

2 | METHODS

2.1 | Study approval

Data from patients who received kisspeptin to trigger oocyte maturation were obtained from randomised clinical trials approved by the Hammersmith and Queen Charlotte’s Research Ethics Committee, London, UK (reference: 10/H0707/2). The trials were registered on the National Institutes of Health Clinical Trials database (NCT01667406) and performed in accordance with the Declaration of Helsinki. All patients included in the study were treated at the IVF Unit at Hammersmith Hospital, London, UK, under a licence from the UK Human Fertilization and Embryology Authority.

2.2 | IVF stimulation protocol

The protocol for patients undergoing kisspeptin triggering has been previously described. Patients triggered with hCG underwent either a GnRH agonist IVF protocol (long protocol), or a GnRH antagonist IVF protocol (short protocol), whereas all patients triggered with GnRH or kisspeptin underwent the short protocol. Recombinant FSH (112.5-250 IU Gonafoll, Merck Serono, Geneva, Switzerland) was used to induce follicular growth in both long and short protocols. Premature ovulation was prevented by pretreatment with the GnRH agonist buserelin (0.2-0.5 mg Suprefact, Sanofi-Aventis, Gentilly, France) in the long protocol, and with a GnRH antagonist—either cetrotrelax (0.25 mg, Cetrotide, Merck Serono, Middlesex, UK) or ganirelax (0.25 mg Orgalutran, Merck Sharp & Dohme Ltd, Hertfordshire, UK) in the short protocol. The trigger was administered once 3 ovarian follicles were ≥18 mm in diameter and oocyte retrieval was conducted 36 hours thereafter. The trigger of oocyte maturation was either hCG—chorio gonadotrophin alpha (0.25 mg,
Ovarian volumes were measured using transvaginal ultrasound to record parameters of OHSS such as ovarian size and the reduction in urine output and underwent transvaginal ultrasound (6.4-12.8 nmol/kg as a single bolus, or 19.2 nmol/kg as a split dosing over 10 hours, Bachem Holding AG, Bubendorf, Switzerland) administered subcutaneously.\textsuperscript{8,10,18}

2.3 | Study participants

Women undergoing IVF treatment for infertility at Hammersmith Hospital, London, UK, between 2013 and 2016 were included in the study (n = 261). We selected patients at high risk of OHSS as defined by a total antral follicle count (AFC) or total follicle count on day of trigger ≥23.\textsuperscript{15}

2.4 | Assessment of early OHSS

Patients were assessed for parameters of early OHSS between days 2 and 6 following oocyte retrieval. For hCG and GnRHa groups, the Hammersmith IVF Unit policy is to screen all patients with at least 18 follicles ≥11 mm on the day of trigger for OHSS (all patients had follicle counts ≥23 on day of trigger in this study). Patients triggered with kisspeptin at high risk of OHSS (AFC ≥23) were part of a clinical trial and thus also screened for OHSS. In all patients, OHSS screening is usually conducted just prior to embryo transfer (either day 3 or day 5 postoocyte retrieval), although it may be conducted between days 2 and 6 following oocyte retrieval to avoid out-of-hours scheduling. During OHSS screening, patients were asked as to the presence of the following symptoms consistent with OHSS (abdominal pain, abdominal bloating, nausea, vomiting, diarrhoea, self-reported reduction in urine output) and underwent transvaginal ultrasound screening to record parameters of OHSS such as ovarian size and the presence of ascites. Ovarian volumes were measured using transvaginal ultrasound (Toshiba Xario Prime, Crawley, UK) by experienced IVF physicians/ultrasonographers at Hammersmith IVF unit, London, UK during 2013-2016 and converted electronically to ovarian volume values using the prolate ellipsoid formula (height × width × depth × 0.523). Patients were objectively graded for OHSS based on modified criteria of Golan et al 1989\textsuperscript{2} as below: Normal—Patients without any symptoms consistent with OHSS. Mild OHSS—Patients with at least one symptom consistent with OHSS and maximal ovarian volume (either left or right ovary) of between 65 and 903 ml (approximated to 5-12 cm diameter). Moderate OHSS—Patients met the criteria for mild OHSS and additionally had at least 50 ml of total ascitic fluid in the pouch of Douglas, adnexae and abdomen. Severe OHSS—if patients met the above criteria for moderate OHSS, but additionally had at least 50 ml of fluid in the pleural space.

2.5 | Statistical analysis

Statistical analysis was conducted by TWK and AA using Graphpad Prism version 7.0 and Stata version 14.0 statistical software. Baseline characteristics were compared using the Kruskal-Wallis test for continuous variables and the Chi squared test for binary variables. Adjusted logistic regression analysis was used to derive odds ratios for experiencing symptoms of OHSS following hCG or GnRHa when compared to kisspeptin. Variables examined as potential confounders included age, body mass index (BMI), AFC, recombinant FSH dose, use of long IVF protocol, number of follicles ≥11 mm on day of trigger and number of oocytes retrieved. Univariate analyses were conducted to determine variables independently associated with both trigger and symptom and adjusted for in the logistic regression model. Odd ratios for abdominal pain and “self-reported reduction in urine output” were adjusted for “use of long IVF protocol.” Odd ratios for abdominal bloating were adjusted for “use of long IVF protocol” and “number of oocytes” retrieved. Odd ratios for diarrhoea were adjusted for AFC and “use of long IVF protocol.” Odds ratios for nausea were adjusted for AFC, “total dose of recombinant FSH during stimulation” and “use of long IVF protocol.” No confounders significantly influenced the likelihood of diagnosis of OHSS and thus unadjusted odds ratios are presented. As no patient with kisspeptin triggering had “self-reported reduction in urine output” or moderate OHSS, Laplace smoothing was applied.

3 | RESULTS

3.1 | Baseline characteristics

Two hundred and sixty-one women at high risk of OHSS received either hCG (n = 40), GnRHa (n = 99), or kisspeptin (n = 122) to trigger oocyte maturation. A further 16 patients in the hCG group, 24 patients in the GnRHa group and 3 patients in the kisspeptin groups were identified who met the criteria for inclusion in the study, but did not have data available and were thus excluded from further analyses. The cohort studied was at high risk of OHSS with a median of 38 antral follicles, 24 follicles ≥11 mm on the day of trigger and 19 oocytes retrieved. There were significant imbalances between the treatment groups as clinicians are more likely to recommend GnRHa trigger rather than hCG trigger for patients deemed at higher risk of OHSS (“Table S1” for baseline characteristics).

3.2 | Ovarian volume and ascitic volume following different triggers

Median ovarian volume at 2-6 days following oocyte retrieval was higher following hCG (138 ml) than following GnRHa (73 ml; \textit{P} < .0001), than following kisspeptin (44 ml; \textit{P} < .0001) (Figure 1A). A multivariate regression analysis adjusted for AFC, body mass index, use of long IVF protocol, average daily recombinant FSH dose, number of follicles ≥11 mm on day of trigger and number of oocytes retrieved revealed an increase in mean ovarian volume of 151 ml (CI 113-189; \textit{P} < .001) following hCG and 29 ml (CI 8-50; \textit{P} = .007) following GnRHa when compared to kisspeptin. Mean total ascitic volume was 62 ml following hCG, 9 ml following GnRHa and 5 ml following kisspeptin (Figure 1D). A multivariate regression analysis adjusted for the same factors as above found that hCG resulted in an
increase of 33 ml (CI 14-52 ml; \( P = .001 \)) of ascitic fluid when compared to kisspeptin.

### 3.3 | Symptoms of OHSS following each trigger

Symptoms of OHSS were most frequent following hCG and least frequent following kisspeptin (Figure 2). Abdominal pain was \( \sim 13 \)-fold more likely following hCG \( ( P < .001) \), and \( \sim 2 \)-fold more likely following GnRHa \( ( P = .048) \) when compared to kisspeptin (Table 1). Abdominal bloating was \( \sim 30 \)-fold more likely following hCG \( ( P < .001) \), and \( \sim 4 \)-fold more likely following GnRHa \( ( P = .005) \) when compared to kisspeptin (Table 1). Nausea was \( \sim 19 \)-fold more likely following hCG \( ( P = .001) \), and \( \sim 8 \)-fold more likely following GnRHa \( ( P = .007) \) when compared to kisspeptin (Table 1).

### 3.4 | Rates of OHSS following each trigger

Mild OHSS occurred in 45% of patients following hCG, 30% following GnRHa and 12% following kisspeptin (Table 2). Moderate to severe OHSS occurred in 37.5% of patients following hCG, 3% following GnRHa and no patient following kisspeptin (Table 2). The likelihood of OHSS was increased at least \( \sim 33 \)-fold following hCG \( ( P < .0001) \) and \( \sim 3 \)-fold following GnRHa \( ( P < .0001) \) when compared to kisspeptin (Table 2).

### 3.5 | Ovarian volume as a marker of OHSS risk

Ovarian volume was larger in patients with more symptoms of OHSS and in patients with increased ascitic volume (Figure S1A-B). Similarly, symptoms of OHSS and ascitic volume were increased in patients with larger ovarian volumes (Figure S1C-D). No patient with a mean ovarian volume <100 ml was diagnosed with moderate to severe OHSS, whereas 16% of patients with mean ovarian volume between 101 and 200 ml and 56% of patients with a mean ovarian volume >200 ml were diagnosed with moderate to severe OHSS.

### 4 | DISCUSSION

This study is the first to compare parameters of early OHSS following hCG, GnRHa and kisspeptin in women at high risk of OHSS. We observed that ovarian volumes following controlled ovarian stimulation recovered closer to baseline prestimulation volumes after GnRHa and kisspeptin than following hCG (ovarian volume was
GnRH nerve terminals. Some pituitary GnRH receptors may not be directly contiguous with serum LH amplitude when compared to kisspeptin, implying that and in the absence of hCG for luteal phase support.

19-22 In severe early OHSS even in patients treated with segmentation case-reports have suggested that GnRHa triggering can still result in increased 20-fold following hCG, 8-fold following GnRHa, 5-fold following kisspeptin; \( P < .0001 \) (Figure 1C). Furthermore, symptoms of OHSS were less frequent following GnRHa and kisspeptin than following hCG (Figure 2 and Table 1). The likelihood of diagnosis of OHSS was less frequent following the induction of endogenous gonadotrophins using GnRHa or kisspeptin than following exogenous hCG (Table 2).

Our results are consistent with the different mechanisms of action of the triggers used in the present cohort study. Accordingly, hCG acts directly on LH-receptors in the ovary and has an excessive duration of action (7-10 days) leading to an increased risk of OHSS.\(^1\) GnRHa has a significantly shorter duration of action than hCG and therefore carries a lower risk of inducing OHSS.\(^1\) Even so, recent case-reports have suggested that GnRHa triggering can still result in severe early OHSS even in patients treated with segmentation and in the absence of hCG for luteal phase support.\(^19-22\) Kisspeptin induces the release of an endogenous pool of GnRHa from the hypothalamus, and thus results in the individualised release of gonadotrophins, which could be of particular value in patients at very high risk of OHSS.\(^10,18\) Indeed, equimolar infusions of GnRHa result in greater serum LH amplitude when compared to kisspeptin, implying that some pituitary GnRH receptors may not be directly contiguous with GnRH nerve terminals.\(^9\)

Data from previous studies have suggested that the observed rates of OHSS following different triggers may not be entirely explained by their relative durations of stimulation and could additionally be due to direct ovarian actions. In this context, hCG has been shown to directly increase VEGF expression and raise VEGF levels in human granulosa cells to increase the risk of OHSS,\(^23-25\) whereas GnRHa may act directly on ovarian GnRH receptors to induce luteolysis to reduce the risk of OHSS.\(^26,27\) Furthermore, the kisspeptin receptor has been hypothesised to play a key role in the pathogenesis of OHSS.\(^28\) Exogenous kisspeptin administration has been reported to reduce VEGF levels via a direct action on ovarian kisspeptin receptors to mitigate the risk of OHSS.\(^28\) This is in keeping with a recent clinical study comparing one or two doses of kisspeptin to trigger oocyte maturation, whereby a second dose of kisspeptin significantly increased the duration of the LH-surge by 4-10 hours in a cohort at high risk of OHSS, but did not result in increased ovarian volume or frequency of OHSS.\(^18\)

Ovarian volume is dramatically enlarged following controlled ovarian stimulation in IVF treatment. The normal range for ovarian volume outside the context of IVF treatment in premenopausal women aged 23-38 years is \(-4-10\) ml.\(^29\) Ovarian volumes have been reported to be 73.4 cm\(^3\) at 5 days after oocyte retrieval following hCG trigger in the short IVF protocol (\(-9\)-fold prestimulation volumes)\(^13\) and \(-22\) cm\(^3\) at 6 days after oocyte retrieval following a GnRHa trigger in women with normal ovarian reserve.\(^11\) Oyesanya and colleagues observed that mean ovarian volumes just prior to hCG trigger were larger in women who later developed moderate to severe OHSS (271 ml) when compared to women who did not develop OHSS (157 ml).\(^30\) These data are consistent with the higher ovarian volumes observed in the present study as our cohort was selected based on follicle count to be at high risk of OHSS.

Due to the frequency of segmentation in patients treated with hCG (51%) or GnRHa (13%) as compared to kisspeptin triggering (3%).
Multivariate analyses

|                       | Univariate analyses | Multivariate analyses |
|-----------------------|---------------------|----------------------|
|                       | Odds ratio (CI)     | p value              | Adj odds ratio (CI) | p value |
| Abdominal pain        |                     |                      |                     |
| hCG                   | 16.1 (6.7-38.3)      | <.001                | 13.1 (4.2-40.6)     | <.001   |
| GnRH                  | 2.1 (1.0-4.2)        | .048                 | 2.1 (1.0-4.2)       | .048    |
| Abdominal bloating    |                     |                      |                     |
| hCG                   | 35.3 (13.9-94.8)     | <.001                | 30.7 (7.0-134.3)    | <.001   |
| GnRH                  | 3.4 (1.7-6.9)        | .001                 | 3.7 (1.5-9.4)       | .005    |
| Diarrhoea             |                     |                      |                     |
| hCG                   | 8.8 (1.6-47.5)       | .011                 | 2.9 (0.2-35.8)      | .41     |
| GnRH                  | 1.9 (0.3-11.6)       | .489                 | 2.4 (0.4-14.9)      | .35     |
| Nausea                |                     |                      |                     |
| hCG                   | 24.8 (6.7-92.3)      | <.001                | 19.4 (3.3-115.4)    | .001    |
| GnRH                  | 6.6 (1.8-23.7)       | .004                 | 8.2 (1.8-37.6)      | .007    |
| Vomiting              |                     |                      |                     |
| hCG                   | 10.1 (1.02-99.9)     | .048                 | 10.1 (1.02-99.9)    | .048    |
| GnRH                  | 5.1 (0.6-46.8)       | .15                  | 5.1 (0.6-46.8)      | .15     |
| Self-reported reduction in urine output |       |                      |                     |
| hCG                   | 13.8 (1.5-127.8)     | .021                 | 16.1 (1.4-188.8)    | .027    |
| GnRH                  | 2.5 (0.2-28.2)       | .45                  | 2.5 (0.2-28.2)      | .45     |

Univariate and multivariate logistic regression analysis of associations between symptom of early OHSS following different triggers. The odds ratio of experiencing symptoms of OHSS following hCG or GnRH trigger when compared with kispeptin trigger is presented as follows: a adjusted for use of long IVF protocol, b adjusted for use of long IVF protocol and number of oocytes retrieved, c adjusted for antral follicle count, d adjusted for antral follicle count and use of long IVF protocol, e adjusted for antral follicle count, total dose of recombinant FSH during stimulation and use of long IVF protocol, f no confounders identified during univariate analysis. As no patient with kispeptin triggering had self-reported reduction in urine output, Laplace smoothing was applied.

TABLE 1 Symptoms of early OHSS using different triggers

|                     | hCG (n = 40) | Normal | Mild OHSS | Moderate OHSS | Severe OHSS | Odds ratio of mild-severe OHSS (95% CI) | Odds ratio of moderate-severe OHSS (95% CI) |
|---------------------|-------------|--------|----------|---------------|-------------|----------------------------------------|---------------------------------------------|
| Abdominal pain      |             | 7 (18%)| 18 (45%) | 9 (23%)       | 6 (15.0%)   | 33.6 (12.6-89.5) P < .0001               | 80.7 (10.2-637.5) P < .0001                  |
| Nausea              |             | 66 (67%)| 30 (30%) | 3 (3%)        | 0 (0%)      | 3.6 (1.8-7.1) P < .0001                 | 5.1 (0.6-46.3) P = .15                      |

The frequency (%) of the number of patients diagnosed with mild, moderate and severe OHSS is presented. Patients were objectively graded based on modified criteria of Golan et al 1989 as below:

Normal—Patients without any symptoms consistent with OHSS were graded as normal.

Mild OHSS—Patients with at least one symptom consistent with OHSS and maximal ovarian volume (either left or right ovary) of 65-903 ml (approximated to 5-12 cm diameter) were graded as mild OHSS.

Moderate OHSS—If patients met the above criteria for mild OHSS and additionally had at least 50 ml of total ascitic fluid in the pouch of Douglas, adnexae and abdomen, they were graded as moderate OHSS.

Severe OHSS—If patients met the above criteria for moderate OHSS, but additionally had at least 50 ml of fluid in the pleural space, they were graded as severe OHSS.

Rates of OHSS were compared by logistic regression: as no baseline variables were significant during univariate analyses, unadjusted odds ratios (95% confidence interval) are presented for hCG and GnRH agonist trigger as compared to kispeptin trigger. Mild to severe OHSS was compared to "no OHSS," whilst moderate-severe OHSS was compared to "normal to mild OHSS."

As no patient with kispeptin was diagnosed with moderate OHSS, Laplace smoothing was applied.
ovarian volume was increased by 214% following hCG and 66% following GnRHa compared to kisspeptin; ≥1 symptom of OHSS was present in 82% following hCG; 43% following GnRHa; 20% following kisspeptin). Additionally, the use of the long IVF protocol was statistically adjusted for when deriving odds ratios for parameters of OHSS. Thus, the published data are consistent with the high rates of symptoms observed in the present study given that this population was at increased risk of OHSS (mean number of oocytes retrieved in this cohort was ~20 as compared to ~9 in the Toftager cohort).13

All patients in this study were treated and assessed at the same centre and no more than 9 different IVF physicians/ultrasoundographers conducted ultrasounds over the 3-year study period. Limitations of the study include that insufficient data on blood results were available to assess for haemoconcentration and thus rates of severe OHSS may be underestimated. Indeed, patients in all three groups were at markedly increased risk of OHSS (median AFC ≥36 in all 3 groups) and the rate of severe OHSS encountered in the hCG group (15%) was consistent with the published literature for women with PCOS.15–17 All patients in the kisspeptin group, 96% of the GnRHa group and 75% of the hCG group had an antral follicle count ≥23, conferring an ~4-fold increased risk of OHSS.15 Remaining patients with antral follicle counts <23 were included in the study (predominantly in the hCG group) if they had ≥23 follicles on the day of trigger (mean number of follicles on day of trigger was 35.9 in these patients suggesting that antral follicle count had been underestimated in these patients). However, this could have led to an underestimate of the difference between the trigger groups.

There were some differences in baseline characteristics between the treatment groups in this retrospective cohort study (Table S1); however, sensitivity analyses suggest that these were unlikely to have significantly altered the findings of this study. In 113 patients with at least 25 follicles ≥11 mm on day of trigger, mean ovarian volumes were (hCG 168.6, GnRHa 98.2, kisspeptin 66.9 ml), rates of mild to severe OHSS (hCG 87.5%, GnRHa 33.9%, kisspeptin 16%) and rates of moderate to severe OHSS were (hCG 37.5%, GnRHa 1.7%, kisspeptin 0%). In 114 patients with at least 20 oocytes retrieved, mean ovarian volumes were (hCG 176 ml, GnRHa 90.7 ml, kisspeptin 60 ml), rates of mild to severe OHSS (hCG 90.5%, GnRHa 32%, kisspeptin 10%) and rates of moderate to severe OHSS were (hCG 28.6%, GnRHa 2.7%, kisspeptin 0%). Whilst there was minor variation in the day of OHSS screening (±0.6 days), 90% of assessments were conducted at 3-5 days following oocyte retrieval and results were similar in 138 patients screened for OHSS only on day 5 following oocyte retrieval (mean ovarian volume: hCG 173.2, GnRHa 73.6, kisspeptin 50.1 ml). Although odds ratios were adjusted for relevant variables to account for differences in baseline characteristics, future prospective randomised clinical trials with objective grading of OHSS are required to confirm the results observed in this study.

In summary, we observe that the likelihood of clinical parameters of early OHSS was higher when triggering oocyte maturation with hCG than following GnRHa or kisspeptin. These results suggest that triggering oocyte maturation by the induction of endogenous gonadotrophin release is preferable to the use of hCG in women at high risk of OHSS.

ACKNOWLEDGEMENTS

This paper presents independent research funded by grants from the MRC, BBSRC and NIHR and supported by the NIHR Clinical Research Facility and Biomedical Research Centre at Imperial College Healthcare NHS Trust. The views expressed are those of the author(s) and not necessarily those of the MRC, BBSRC, the NHS, the NIHR or the Department of Health. The Section of Endocrinology and Investigative Medicine is funded by grants from the MRC, BBSRC, NIHR and is supported by the NIHR Biomedical Research Centre Funding Scheme. AA and ANC are supported by National Institute of Health Research (NIHR) Clinical Lectureships. SAC is supported by funding from an NIHR Research Professorship. WSD is supported by an NIHR Research Professorship.

CONFLICT OF INTEREST

All authors declare that they have no competing interests.

AUTHOR CONTRIBUTION

All authors provided contributions to study conception and design, acquisition of data or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, and final approval of the version to be published. Here are the most important contributions of each author: AA and WSD designed the study. Data were collected by AA, SC and RI. Analysis was carried out by TWK and AA. WSD takes final responsibility for this article.

ORCID

W. S. Dhillo http://orcid.org/0000-0001-5950-4316

REFERENCES

1. Delvigne A. Epidemiology of OHSS. Reprod Biomed Online. 2009;19:8-13.
2. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430-440.
3. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249-261. Accessed September 3, 2016.
4. Mathur RS, Akande AV, Kray SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901-907.
5. Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev 2017:1:CD012103.
6. Calhaz-Jorge C, De Geyter C, Kupka MS, et al. Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE. Hum Reprod. 2016;31:1638-1652.
7. Sunderam S, Kissin DM, Crawford SB, et al. Assisted reproductive technology surveillance — United States, 2014. MMWR Surveill. Summ. 2017;66:1-24.
8. Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124:3667-3677.
9. Jayasena CN, Abbara A, Narayanaswamy S, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod. 2015;30:1934-1941.
10. Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger Oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100:3322-3331.
11. Vuong TNL, Ho MT, Ha TD, Phung HT, Huynh GB, Humaidan P. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertil Steril. 2016;105:356-363.
12. Humaidan P, Nelson SM, Devroey P, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod. 2016;31:1997-2004.
13. Toftager M, Bogstad J, Bryndorf T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod. 2016;31:1253-1264.
14. Wada I, Matson PL, Troup SA, Lieberman BA. Assisted conception using buserelin and human menopausal gonadotrophins in women with polycystic ovary syndrome. Br J Obstet Gynaecol. 1993;100:365-369.
15. Jayaparakasan K, Herbert M, Moody E, Stewart JA, Murdoch AP. Estimating the risks of ovarian hyperstimulation syndrome (OHSS): implications for egg donation for research. Hum Fertil (Camb). 2007;10:183-187.
16. Swanton A, Storey L, McVeigh E, Child T. IVF outcome in women with PCOS, PCO and normal ovarian morphology. Eur J Obstet Gynecol Reprod Biol. 2010;149:68-71.
17. Jacob SL, Brewer C, Tang T, Picton HM, Barth JH, Balen AH. A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomized placebo-controlled trial. Hum Reprod. 2016;31:2756-2764.
18. Abbara A, Clarke S, Islam R, et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Hum Reprod. 2017;32:1915-1924.
19. Ling LP, Phoon JWL, Lau MSK, et al. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at "freeze-all strategy". Reprod Biomed Online. 2014;29:392-394.
20. Oriveto R, Vanni VS. Ovarian hyperstimulation syndrome following GnRH agonist trigger—think ectopic. J Assist Reprod Genet. 2017;34:1161-1165.
21. Mahajan N, Gupta S, Sharma S, Rani K, Naidu P, Arora PR. Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis. J Hum Reprod Sci. 2015;8:234-238.
22. Santos-Ribeiro S, Polyzos NP, Stouffs K, et al. Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”, in-depth analysis of genetic predisposition. J Assist Reprod Genet. 2015;32:1063-1068.
23. Cerrillo M, Rodriguez S, Mayoral M, Pacheco A, Martinez-Salazar J, Garcia-Velasco JA. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction. Fertil Steril. 2009;91(4 suppl):1526-1528.
24. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohí J, Simón C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril. 1999;71:482-489.
25. Neulen J, Yan Z, Raczek S, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 1995;80:1967-1971.
26. Casper RF, Yen SS. Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. Science. 1979;205:408-410.
27. Lemay A, Labrie F, Belanger A, Raynaud J. Luteolytic effect of intranasal administration of [D-Ser(TBU)6, DES-Gly-NH2(10)]-luteinizing hormone-releasing hormone ethylamide in normal women. Fertil Steril. 1979;32:646-651.
28. Zhai J, Liu J, Zhao S, Zhao H, Chen ZJ, Du Y, Li W, Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion. Reproduction. 2017;154:355-362.
29. Kelsey TW, Dodwell SK, Wilkinson AG, et al. Ovarian volume throughout life: a validated normative model. PLoS ONE. 2013;8:e71465.
30. Oyesanya O, Parsons J, Collins W, Campbell S. Prediction of oocyte recovery rate by transvaginal ultrasonography and color Doppler imaging before human chorionic gonadotropin administration in in vitro fertilization cycles. Fertil Steril. 1996;65:806-809.
31. Chen ZJ, Shi Y, Sun Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016;375:523-533.
32. Courbiere B, Oborski V, Braunstein D, Desparoir A, Noizet A, Gamerre M. Obstetric outcome of women with in vitro fertilization pregnancies hospitalized for ovarian hyperstimulation syndrome: a case-control study. Fertil Steril. 2011;95:1629-1632.
33. Haas J, Baum M, Meridor K, et al. Is severe OHSS associated with adverse pregnancy outcomes? Evidence from a case-control study. Reprod Biomed Online. 2014;29:216-221.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Abbara A, Islam R, Clarke SA, et al. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment. Clin Endocrinol (Oxf). 2018;88:920–927. https://doi.org/10.1111/cen.13569